What’s hot at ASCO? And what just went cold? Our panel of experts will examine the top stories to come out of the year’s big cancer drug conference.
China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications. With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs. Learn the latest on the clinical trial landscape and infrastructure in China and join Novotech’s DCT partner, Obvio Health, as they share DCT strategies for patient-centric, oncology study design and execution.
ROS1 is quickly emerging as a cancer target for lung cancer. ROS1 fusion mutations occur in 1-2% of non-small cell lung cancer (NSCLC) patients. In 2020, an estimated 1.8 million new cases of NSCLC were diagnosed globally. Next-generation ROS1 inhibitors such as taletrectinib are in development, which may have long durability of response, overcome drug resistance and cross the blood-brain barrier. AnHeart along with a panel of experts will examine some of the leading ROS1 programs and take a look at the latest precision oncology therapeutics being evaluated in the clinic for lung cancer.